Pharm
Vonoprazan
search
Vonoprazan
, Voquezna, Takecab
See Also
Potassium Competitive Acid Blocker
Helicobacter Pylori
Gastroesophageal Reflux
Indications
Erosive
Esophagitis
Nonerosive
Gastroesophageal Reflux
Disease
Helicobacter Pylori
Mechanism
Potassium Competitive Acid Blocker
(
PCAB
)
Similar mechanism as
Proton Pump Inhibitor
s (PPIs)
In addition to blocking active proton pumps (as with PPIs),
PCAB
s also block resting proton pumps
Allows for
PCAB
onset of activity within hours (as compared with days for PPIs)
PCAB
s may be taken with or without food (contrast with PPIs taken 60 minutes before eating)
Dosing
By Indications
See indications for low dose (10 mg/day) in renal and liver disease as below
Healing of Erosive
Esophagitis
and
GERD
Relief
Vonoprazin 20 mg orally daily for 8 weeks
Decrease dose to 10 mg orally daily if GFR <30 ml/min
Maintenance of Healed Erosive
Esophagitis
and
GERD
Relief
Vonoprazin 10 mg orally daily for up to 6 months
Nonerosive
GERD
Vonoprazin 10 mg orally daily for 4 weeks
Helicobacter Pylori
Vonoprazan 20 mg orally twice daily AND
Antibiotic
s
Packaged with
Antibiotic
s (
Amoxicillin
and
Clarithromycin
)
Voquezna Triple Pak (Vonoprazan,
Amoxicillin
,
Clarithromycin
)
Voquezna Dual Pak (Vonoprazan,
Amoxicillin
)
However, no evidence for greater efficacy for
PCAB
s than the much lower cost
Proton Pump Inhibitor
s
Lower efficacy than quadruple therapy
At $800 in 2022, the cost is four fold higher than standard quadruple therapy
Dosing
By Strength
High Dose: 20 mg orally twice daily
Helicobacter Pylori
Management
Moderate Dose: 20 mg orally daily
Gastric Ulcer
or
Duodenal Ulcer
Gastroesophageal Reflux
(
GERD
)
Low Dose: 10 mg orally daily
Reflux Esophagitis
prevention
Aspirin
or
NSAID
induced
Peptic Ulcer
prevention
Renal Dosing
(GFR <30 ml/min)
Child-Pugh Class
B or C
NOT recommended for
Helicobacter Pylori
Efficacy
Vonoprazin is $200/month (up to $650/month) in 2026 (far more expensive than PPIs)
Vonoprazin has shown no benefit over
Proton Pump Inhibitor
s (PPIs)
Vonoprazin 20 mg is similar to
Lansoprazole
(
Prevacid
) 30 mg for erosive
Esophagitis
healing at 4 weeks
Vonoprazin is not better than PPIs for the prevention and treatment of
Peptic Ulcer Disease
(gastric or duodenal)
Simadibrata (2024) Dig Dis Sci 69(10):3863-74 +PMID: 39294424 [PubMed]
Adverse Effects
Diarrhea
Nausea
Longterm adverse effects are similar to
Proton Pump Inhibitor
s
Increased
Fracture
risk
Clostridioides difficile
Vitamin B12 Deficiency
Hypomagnesemia
(and
Hypokalemia
,
Hypocalcemia
)
Atypical and rare serious effects
Fundic gland polyps
Acute Tubulointerstitial Nephritis
Stevens Johnson Syndrome
Toxic Epidermal Necrolysis
Safety
Unknown safety in pregnancy
Unknown safety in
Lactation
Drug Interactions
CYP3A4
Inducers
Decrease Vonoprazin efficacy
Resources
Vonoprazin (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cc52ac5-77ec-4d66-a770-762a1a960914
References
(2024) Presc Lett 31(1): 5
Type your search phrase here